CD44 and neoplasm: In vivo limiting dilution assays revealed that the loss of PCAT6 dramatically reduced tumor incidence (Figure 3e), and reduced CD44+ breast CSCs, c‐MYC, and Ki67 were detected in PCAT6 knockdown cell‐formed xenografts compared with control xenografts (Figure 3f).